IMPORTANT: PREGABALIN AND GABAPENTIN CONSULTATION PROPOSALS – TO SCHEDULE UNDER THE MISUSE OF DRUGS REGULATIONS – TO INCLUDE SAFE CUSTODY.
Pregabalin and gabapentin: proposal to schedule under the Misuse of Drugs Regulations 2001
This consultation is open until 22nd January 2018.
Please see options listed below – you may wish to respond given the potential impact on storage capacity and stock management.
There are three options:
1) Control pregabalin and gabapentin as Class C Drugs under the 1971 Act and place both in Schedule 3 to the 2001 Regulations, applying the provisions of the Misuse of Drugs (Safe Custody) Regulations 1973 (the 1973 Regulations).
2) Control pregabalin and gabapentin as Class C Drugs under the 1971 Act and place both in Schedule 3 to the 2001 Regulations (but exclude the application of safe custody requirements).
3) Control pregabalin and gabapentin as Class C Drugs under the 1971 Act and place both in Part 1 of Schedule 4 to the 2001 Regulations.
This consultation seeks views on options whether, and how, to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 following the recommendation by the Advisory Council on the Misuse of Drugs (ACMD) that these 2 drugs should be controlled as Class C drugs under the Misuse of Drugs Act 1971 (‘the 1971 Act’) and placed in Schedule 3 to the Misuse of Drugs Regulations 2001.
The consultation is aimed at members of the public, healthcare professionals, institutions, all sectors within the supply chain including the pharmaceutical industry, wholesalers and community pharmacies in the UK.
Comments from all those with an interest in the consultation are welcome.